Application of a monoclonal antibody in the treatment of psoriasis

A monoclonal antibody, psoriasis technology, applied in the direction of antibodies, medical preparations containing active ingredients, skin diseases, etc., can solve the problems of easy recurrence and large side effects

Active Publication Date: 2019-10-18
INNOVENT BIOLOGICS (SUZHOU) CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, there is no effective treatment for psoriasis. Commonly used drugs include glucocorticoids, methotrexate, cyclosporine A, and biological therapy. Tolerance, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a monoclonal antibody in the treatment of psoriasis
  • Application of a monoclonal antibody in the treatment of psoriasis
  • Application of a monoclonal antibody in the treatment of psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Embodiment 1 Psoriasis therapeutic effect of bifunctional monoclonal antibody of the present invention

[0047] 1. Method

[0048] 1.1 Experimental objects and materials:

[0049] Balb / c mice, male, weighing 18-22 grams, Beijing Huafukang Biotechnology Co., Ltd., the quality certificate of experimental animals: SCXK (Beijing) 2009-0007.

[0050] Imiquimod ointment: Sichuan Mingxin Pharmaceutical Co., Ltd., content: 5%, batch number: 130901;

[0051] IBI-B: Innovent Biopharmaceutical (Suzhou) Co., Ltd., concentration: 40 mg / ml, batch number: E20140402;

[0052] Methotrexate: Jiangsu Hengrui Pharmaceutical Co., Ltd., specification: 100 mg / bottle, batch number: 20131103

[0053] 1.2 Grouping and administration

[0054] The mouse model of psoriasis was prepared by referring to the method of Leslie et al. [1]. According to the previous research results of our laboratory, Balb / c male mice were anesthetized by intraperitoneal injection of pentobarbital sodium (80mg / kg), an...

Embodiment 2

[0124] Example 2 The inhibitory effect of the bifunctional monoclonal antibody of the present invention on the VEGF signaling pathway

[0125] 1. Experimental materials:

[0126] EndoGRO-VEGF Complete Culture Media Kit: Millipore SCME002

[0127] DMEM medium: Gibco 11966-025

[0128] VEGF 165 : Peprotech 100-20

[0129] CCK-8: Sigma 96992

[0130] 2. Experimental steps:

[0131] 2.1 Digest and count HUVECs with good growth status.

[0132] 2.2 Resuspend endothelial cells with Millpore medium to 2X10 4 cells / ml, spread 2000 / well HUVECs (100ul) on a 96-well plate.

[0133] 2. After 324 hours, the medium was aspirated and replaced with DMEM dual medium containing 10ng / ml VEGF and 35nM IgG, VEGF-Trap, CR1, IBI-B, and a negative control without VEGF and a positive control containing VEGF but no antibody were set. A blank control with only PBS was also included. Three replicate wells were set up in each group for parallel experiments.

[0134] 2.4 After another 48 hours, a...

Embodiment 3

[0138] Example 3 The inhibitory effect of the bifunctional monoclonal antibody of the present invention on the complement signaling pathway

[0139] 1.CH50 hemolysis test

[0140] 1.1 Experimental materials:

[0141] Sheep red blood cells: Guangzhou Ruite 007001

[0142] Hemolysin: Guangzhou Ruite

[0143] Human complement serum: Sigma S1764

[0144] Buffer GVB0: 0.1% gelatin, 5mM barbiturate, 145mM NaCl, adjust the pH to 7.2-7.4 and dilute to 1L

[0145] GVB++: 0.1% gelatin, 5mM barbiturate, 145mMNaCl, 0.15mM CaCL2, 0.5mMMgCL2, adjust the pH to 7.2-7.4 and then dilute to 1L

[0146] 0.1M sucrose GVB: Add 5.14g sucrose to 150ml GVB0

[0147] GVB-EDTA: 0.1% gelatin, 5mM barbiturate, 145mM NaCl, 10mM EDTA, adjust the pH to 7.2-7.4 and dilute to 1L

[0148] The above buffer nights were sterilized by high temperature and high pressure sterilizer before use

[0149] 1.2 Experimental steps:

[0150] 1.2.1 Sensitized sheep red blood cells

[0151] a. Wash sheep erythrocytes ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of a bifunctional monoclonal antibody in the treatment of psoriasis. Specifically, the present invention provides the use of a monoclonal antibody for preparing a pharmaceutical composition for treating psoriasis; wherein, the monoclonal antibody has a sequence as shown in SEQ ID NO.:1. Experiments have proved that the monoclonal antibody of the present invention has a therapeutic effect on psoriasis by inhibiting complement and synergistically inhibiting VEGF, and the effect is equivalent to that of the positive control group, and the effect has significant dose dependence.

Description

technical field [0001] The term biomedical field of the present invention, specifically, relates to the application of a monoclonal antibody in psoriasis. Background technique [0002] Psoriasis, commonly known as psoriasis, is a chronic inflammatory skin disease with a long course of disease and a tendency to relapse, and some cases are almost unhealed throughout life. The disease mainly occurs in young and middle-aged people, and has a great impact on the physical health and mental status of patients. The clinical manifestations are mainly erythema and scales, and the disease can occur all over the body. The scalp and the extensor sides of the limbs are more common, and it usually aggravates in winter. The pathogenesis is complex, and it is currently believed to be related to genetics, infection, immune response, endocrine abnormalities, and mental factors. [0003] At present, there is no effective treatment for psoriasis. Commonly used drugs include glucocorticoids, me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/395A61K45/00A61P17/06
Inventor 李佳王春明俞德超
Owner INNOVENT BIOLOGICS (SUZHOU) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap